| Speakers from |
 |
Xencor
AstraZeneca
Merck Serono
Pfizer, Inc
Novartis Institutes for Biomedical Research
F.Hoffmann-La Roche AG
Novartis Vaccines and Diagnostics, Inc.
Novo Nordisk A/S
Affibody
Pfizer
Amgen Inc.
AstraZeneca (Tentative)
Avecia Biologics
Bayer Schering AG
Imperial College London
University of Cambridge
Antitope
Morphosys
Tebu-Bio
Invitrogen
|
|
|
|
|
| Featured Speakers |
|
|
|
Dr. Andrei A. Raibekas,
Principal Scientist Protein Formulation, Amgen Inc.
|
 |
|
|
Dr. Mark Abbott,
Principal Scientist, Respiratory and Inflammation, AstraZeneca (Tentative)
|
|
|
|
Dr. Hanne B. Rasmussen,
Head of Department, Dep. of Protein Structure and Biophysics, Novo Nordisk A/S
|
|
|
|
Dr Alexandra Baer,
Senior Scientist, Symphogen
|
|
|
|
Dr Matthew Baker,
CSO, Antitope Ltd
|
|
|
|
Dr. Lucia Banci,
Professor of Chemistry, Magnetic Resonance Center and Department of Chemistry, University of Florence
|
|
|
|
Dr Amrik Basran,
Director, Discovery Biosciences, Biopharm CEDD, Domantis
|
|
|
|
Dr Peter Buckel,
Chief Executive Officer, Suppremol GmbH, Germany
|
|
|
|
Dr Neil Butt,
Business Development Director, Antitope
|
|
|
|
Laurent Chevalet,
Head, Protein Biochemistry Department, Merck Serono
|
|
|
|
Dr Hans-Jürgen Christian,
Head of Process Development, Pieris AG
|
|
|
|
Dr. Ciaran Cronin,
Head, Group Parallel Protein Production, Structural Biology, Pfizer, Inc
|
|
|
|
Dr Niek Dekker,
Head, Protein Biochemistry Department, Associate Director, Protein Engineering, Global Structural Chemistry
|
|
|
|
Michael Dyson,
Senior Research Associate, Department of Biochemistry, University of Cambridge
|
|
|
|
Dr Reinhard Ebner,
Vice President Genomics and Biomarkers, ActoKine Therapeutics
|
|
|
|
Dr Georg Feger,
Worldwide Head of Protein & Cell Science, Merck Serono
|
|
|
|
Dr Stephan Fischer,
Senior Vice President, Biologics Research and Strategy, Roche Pharma Research, Germany
|
|
|
|
Prof. Göran Forsberg,
VP Communication & Business Development, Active Biotech AB
|
|
|
|
Dr Bernd Gehartz,
Unit Head, Director, Novartis
|
|
|
|
Prof. Udo Heinemann,
Head of Protein Sample Production Facility, Max Delbrueck Center for Molecular Medicine, Berlin, Germany
|
|
|
|
Dr. Ian Hodgson,
Head of Molecular Biology, ECS, Avecia Biologics
|
|
|
|
Dr Ian Hunt,
Laboratory Head, Novartis Institutes for Biomedical Research
|
|
|
|
Dr Stephen Irving,
Senior Principle Scientist, Structural Biology and Biophysics, Pfizer
|
|
|
|
Joerg Knaeblein,
Core Technology Scouting, Global Drug Discovery, Operations / Collaborations, Bayer Schering AG
|
|
|
|
Dr. Ulrike Korf,
Scientist, German Cancer Research Centre
|
|
|
|
Dr Karol Kozak,
Database Implementation, High Content Screening, RISC, Eth Zurich
|
|
|
|
Dr. Harald Kropshofer,
Global Coordinator Immunosafety, F.Hoffmann-La Roche AG
|
|
|
|
Dr. Roland Leathers,
Field Application Specialist, Invitrogen
|
|
|
|
Prof. Dr. Melvyn Little,
Chief Scientific Officer, Affimed Therapeutics AG
|
|
|
|
Dr Stefan Masure,
Principal Scientist Drug Discovery, Head of Protein Production, Department of Assay Development & HTS, Johnson & Johnson Pharmaceutical Research & Development
|
|
|
|
Mark McAlister,
Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca
|
|
|
|
Dr. Judit Nagy,
Proteomics Facility Director, Institute of Biomedical Engineering, Imperial College London
|
|
|
|
Dr Fredrik Nilsson,
Project Manager Biopharmaceuticals, Affibody
|
|
|
|
Dr. Andreas Popp,
Group Leader Protein Production, Morphosys
|
|
|
|
Dr Paul Ramage,
Group Leader, Protein Preparation, Protein Structure Unit, Novartis Institutes for Biomedical Research
|
|
|
|
Senior Representative,
Tebu-Bio
|
|
|
|
Senior Representative,
Invitrogen
|
|
|
|
Senior Representative,
Sloning Biotech
|
|
|
|
Stefan Schmidt,
Team Leader Protein Science, Astra Zeneca
|
|
|
|
Dr. Indresh Srivastava,
Acting Head of Protein Biochemistry, Novartis Vaccines and Diagnostics, Inc.
|
|
|
|
Prof. Joel L. Sussman,
Pickman Prof. of Structural Biology , Department of Structural Biology, Weizmann Institute of Science
|
|
|
|
David Szymkowski,
Senior Director, Biotherapeutics, Xencor
|
|
|
|
Dr. Markus Templin,
Head Assay Development, Natural and Medical Science Institute, University of Tübingen
|
|
|
|
|
|
